The Lab supports PhD students, post-doctoral researchers, engineers and researchers who aspire for in entrepreneurial adventure and start-up. To support business start-up projects, the unit relies on SAYENS, CNRS Innovation, and DECA-BFC (Bourgogne Franche-Comté Incubator). It also benefits from the support of the Bourgogne-Franche-Comté Region through the ICE (“Initiative Chercheurs Entrepreneurs”) annual program.
Transfer unit BIOCONJUGATES
Bioconjugation and radiolabeling solutions for the preparation of radiopharmaceuticals and theranostics
In 2015, ICMUB set up a specific transfer and valorisation activity to facilitate fruitful interactions with local industrial players in the healthcare sector, particularly in the fields of molecular imaging and targeted radiotherapy. This structure, known as the Transfer Unit, now plays an important role in regional economic development around theranostic radiopharmaceuticals. By integrating the full range of services offered by local partners (Oncodesign Service, CheMatech, CGFL), which is attracting numerous biotech companies in the field (USA, EU, Japan), ICMUB can improve its visibility and enhance its knowledge of future needs and the technological challenges to be overcome. Through its Transfer Unit, ICMUB also supports academic laboratories in their R&D work by offering them custom conjugation and radiochemistry services.
Contact : claire.bernhard@ube.fr
More information:
The service offering includes the development of bioconjugation protocols (labelling with chelating agents such as DOTA for nuclear imaging, fluorophore for optical imaging, or a combination of both for bimodal applications). The process is defined as follows:
We can also support customers and researchers for the set-up of radiochemitry protocols (Zr89, Cu64, In111, Ga68, Lu177, Ac225).
The + of the transfer unit:
- Internationally recognized expertise in the chemistry of chelating agents and fluorescent probes.
- Solid know-how in radiochemistry (Zr89, Cu64, Ga68, In111, Lu177 studies) and privileged access to a preclinical imaging platform (IMATHERA platform – CGFL).
- Protocols for synthesizing bioconjugates adapted to the problem being addressed.
- State-of-the-art equipment for characterising bioconjugates.
Stratefic partners:
Involved members:
- Scientific manager: Dr. Claire BERNHARD
- Technical experts – Radiochemistry and Bioconjugation : Dr. Mathieu MOREAU, Dr. Michael CLARON (RITM team)
- Scientific advisors: Pr. Franck DENAT, Dr. Victor GONCALVES, Dr. David MONCHAUD, Pr. Anthony ROMIEU (RITM and SMOL teams)
Our start-ups in incubation stage
INNOVATION FOR HEALTH: a new solution for Fluorescence Image guided Surgery (Oncology)
FLUONIR is a start-up project in the healthcare field, and results from Amélie GODARD and Malorie PRIVAT’s PhD works at ICMUB, in collaboration with IAB (UMR 5039, Grenoble). The future start-up is interested in developing fluorescent molecules coupled to biological vectors, which can be injected before surgery to obtain specific and stable labeling of the tumour areas to be eliminated. With this patented innovation, FLUONIR aims to provide a reliable, customizable and accurate tool for real-time identification of tumours thanks to the fluorescence emanating from the molecules during surgery.
Support: LINSKIUM and DECA-BFC incubators, RISE CNRS innovation program (2024)
Award: IphD 2022 “Grand Prix” winner (Dr. A. Godard)
Staff members involved: Dr. Christine Goze (SMOL team)
An innovative solution for solid-state hydrogen storage
The aim of our project, H2 SOLIDE, is to offer a solid, compact and safe hydrogen storage solution. By avoiding any gaseous or liquid storage, we are aiming to take advantage of the presence of hydrogen atoms in chemical compounds, in the form of a white, compact, non-hazardous and regenerable powder. In this way, we promise to make hydrogen storage three times more compact than highly pressurised systems, with controlled delivery of carbon-free hydrogen. We are currently developing a laboratory proof-of-concept for a fuel cell power supply.
Support: SATT SAYENS, DECA-BFC Incubator, RISE CNRS innovation class of 2023
Award: IphD 2024 “Grand Prix” winner
Staff members involved : Pr. Jean-Cyrille HIERSO, Didier POINSOT (CapCOM team).
Our active companies
Expertise : Design and synthesis of chelating agents (DOTA, NOTA derivatives, …) for the preparation of imaging agents, radiopharmaceuticals for PET and SPECT imaging or Molecular radiotherapy
Founding date: 2005
Expertise : expert in the synthesis of Porphyrines, Phthalocyanines and derivatives for research and industry.
Founding date: 2013
Expertise : SON SAS is a pioneering leader in the field of nanoengineering, specialising in the design and production of HIGH-PRECISION nanoparticles.
Founding date: 2020